Compare Adaptive Biotechnologies Corp (ADPT) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs D Wave Quantum Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.89 (market cap $3.33B), while D Wave Quantum Inc trades at $20.37 (market cap $7.80B). The key difference: D Wave Quantum Inc is far larger — about 2.3× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | QBTS | |
|---|---|---|
Market Cap | $3.33B | $7.80B |
Sector | Health | Technology |
52-Week High | $22.37 | $44.78 |
52-Week Low | $10.24 | $12.98 |
Enterprise Value | $3.19B | $7.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
D-Wave Quantum (QBTS) trades at $22.56, up 0.11% on the day, amid a bearish technical signal from moving averages. The company reported a net loss of $355.06 million on $24.59 million revenue in 2025, with a negative net income margin of -2,957.23%. Recent positive developments include being named a Leader in the IDC MarketScape quantum computing assessment and securing a $1.5 million NSF grant.
Despite unanimous analyst buy ratings and a $39.86 consensus price target, significant risks include extreme cash burn, negative profitability, and the speculative nature of quantum computing commercialization. The stock's high P/S ratio of 619.05 reflects growth expectations but underscores valuation sensitivity to execution milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
